Decoy Therapeutics is trading 11.87% down now at $2.45 after no fresh company-specific catalyst was identified for September 21, 2026.

  • The latest notable disclosure was September 15 shareholder approval of warrant issuance and a reduction in authorized shares; that event predates today’s decline.
  • The broader market is strongly higher, so Decoy Therapeutics is not following the prevailing risk-on direction.
  • Available coverage shows no current headlines, leaving the immediate cause unclear.